Therapeutically-induced autoantibodies in patients treated with recombinant hematopoietic growth factors

A brief summary

Takashi Kato, Hiroshi Miyazaki

    Research output: Contribution to journalArticle

    4 Citations (Scopus)

    Abstract

    Since recombinant gene technology was established to provide rare important regulatory proteins as recombinant molecules, cytokine therapies have widely developed and enormously contributed to the treatment of various diseases; nevertheless, it has been revealed that recombinant therapeutic molecules are not always perfect because of side-effects related to pharmacological functions of cytokines and/or potential antigenicity observed in some clinical cases. Although studies on the antigenicity of recombinant proteins have initiated, and observations in clinical studies have been accumulated over this decade, mechanisms of the autoantibody production are not clarified yet. Among various hematopoietic growth factors introduced into clinical trials, this report summarizes current issues of autoantibodies to primary regulators for terminal hematopoiesis.

    Original languageEnglish
    Pages (from-to)1129-1132
    Number of pages4
    JournalCurrent Pharmaceutical Design
    Volume9
    Issue number14
    DOIs
    Publication statusPublished - 2003

    Fingerprint

    Autoantibodies
    Intercellular Signaling Peptides and Proteins
    Recombinant Proteins
    Cytokines
    Hematopoiesis
    Therapeutics
    Clinical Trials
    Pharmacology
    Technology
    Genes
    Clinical Studies

    Keywords

    • Anemia
    • Autoantibody
    • Cytokine
    • Erythropoietin
    • G-CSF
    • Hematopoietic growth factor
    • PEG-rHuMGDF
    • Thrombocytopenia
    • Thrombopoietin

    ASJC Scopus subject areas

    • Molecular Medicine
    • Pharmacology, Toxicology and Pharmaceutics(all)

    Cite this

    Therapeutically-induced autoantibodies in patients treated with recombinant hematopoietic growth factors : A brief summary. / Kato, Takashi; Miyazaki, Hiroshi.

    In: Current Pharmaceutical Design, Vol. 9, No. 14, 2003, p. 1129-1132.

    Research output: Contribution to journalArticle

    @article{c455266b72a445259b9f6ee352a92332,
    title = "Therapeutically-induced autoantibodies in patients treated with recombinant hematopoietic growth factors: A brief summary",
    abstract = "Since recombinant gene technology was established to provide rare important regulatory proteins as recombinant molecules, cytokine therapies have widely developed and enormously contributed to the treatment of various diseases; nevertheless, it has been revealed that recombinant therapeutic molecules are not always perfect because of side-effects related to pharmacological functions of cytokines and/or potential antigenicity observed in some clinical cases. Although studies on the antigenicity of recombinant proteins have initiated, and observations in clinical studies have been accumulated over this decade, mechanisms of the autoantibody production are not clarified yet. Among various hematopoietic growth factors introduced into clinical trials, this report summarizes current issues of autoantibodies to primary regulators for terminal hematopoiesis.",
    keywords = "Anemia, Autoantibody, Cytokine, Erythropoietin, G-CSF, Hematopoietic growth factor, PEG-rHuMGDF, Thrombocytopenia, Thrombopoietin",
    author = "Takashi Kato and Hiroshi Miyazaki",
    year = "2003",
    doi = "10.2174/1381612033455044",
    language = "English",
    volume = "9",
    pages = "1129--1132",
    journal = "Current Pharmaceutical Design",
    issn = "1381-6128",
    publisher = "Bentham Science Publishers B.V.",
    number = "14",

    }

    TY - JOUR

    T1 - Therapeutically-induced autoantibodies in patients treated with recombinant hematopoietic growth factors

    T2 - A brief summary

    AU - Kato, Takashi

    AU - Miyazaki, Hiroshi

    PY - 2003

    Y1 - 2003

    N2 - Since recombinant gene technology was established to provide rare important regulatory proteins as recombinant molecules, cytokine therapies have widely developed and enormously contributed to the treatment of various diseases; nevertheless, it has been revealed that recombinant therapeutic molecules are not always perfect because of side-effects related to pharmacological functions of cytokines and/or potential antigenicity observed in some clinical cases. Although studies on the antigenicity of recombinant proteins have initiated, and observations in clinical studies have been accumulated over this decade, mechanisms of the autoantibody production are not clarified yet. Among various hematopoietic growth factors introduced into clinical trials, this report summarizes current issues of autoantibodies to primary regulators for terminal hematopoiesis.

    AB - Since recombinant gene technology was established to provide rare important regulatory proteins as recombinant molecules, cytokine therapies have widely developed and enormously contributed to the treatment of various diseases; nevertheless, it has been revealed that recombinant therapeutic molecules are not always perfect because of side-effects related to pharmacological functions of cytokines and/or potential antigenicity observed in some clinical cases. Although studies on the antigenicity of recombinant proteins have initiated, and observations in clinical studies have been accumulated over this decade, mechanisms of the autoantibody production are not clarified yet. Among various hematopoietic growth factors introduced into clinical trials, this report summarizes current issues of autoantibodies to primary regulators for terminal hematopoiesis.

    KW - Anemia

    KW - Autoantibody

    KW - Cytokine

    KW - Erythropoietin

    KW - G-CSF

    KW - Hematopoietic growth factor

    KW - PEG-rHuMGDF

    KW - Thrombocytopenia

    KW - Thrombopoietin

    UR - http://www.scopus.com/inward/record.url?scp=0037265544&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0037265544&partnerID=8YFLogxK

    U2 - 10.2174/1381612033455044

    DO - 10.2174/1381612033455044

    M3 - Article

    VL - 9

    SP - 1129

    EP - 1132

    JO - Current Pharmaceutical Design

    JF - Current Pharmaceutical Design

    SN - 1381-6128

    IS - 14

    ER -